News资讯中心
- Genesis obtained the registration certification of RSV /ADV Antigen Rapid test kits
- Geneis participate in AACC meeting at Chicago
- Genesis participate in the 63rd China International Medical Equipment Fair(CMEF 2010 Spring)
- Genesis participate American Association of Clinical Chemistry's (AACC)
- Exhibition Information 2013
- Geneis participate in Düsseldorf Messe MEDICA – International Trade Fair & Congress for Medicine
- GENESIS Launched Mycoplasma Pneumoniae
Antigen Rapid Diagnostic Test Kit - Genesis’ Sales & Marketing Center was launched
- Paper: Rapid diagnosis of Mycoplasma pneumoniae in children with pneumonia by an immuno-chromatographic antigen assay
- Overview of Influenza Surveillance in China
- Collection of Technical Documents for Chinese National Influenza Center
- Infectivity, Transmission, and Pathology of Human-Isolated H7N9 Influenza Virus in Ferrets and Pigs
- China's new WHO flu monitoring center seeks to reverse criticism
- No child should die of TB.
- Tuberculosis is a global pandemic
- XDR-TB has been confirmed in more than 100 countries around the world
- Efforts to contain the spread of the tenacious form of TB have proven insufficient, and HIV clinics and hospitals have become the most likely source of infectio
No child should die of TB.
Time：2016-05-24Each year, 1 million children get sick with TB and 140,000 needlessly die. That's nearly 400 children dying each and every day.
TB Alliance and partners are working to solve this problem. Around the world, most children don’t have access to TB medicines in the proper doses or formulations. Care providers and parents have to crush or chop adult pills to approximate the correct dose for children. This is a daily struggle—for six long months-- and creates a guessing game of whether children receive the right dose. Ultimately, these medicines can negatively impact adherence, outcomes, and fuel the development of drug-resistant TB.
TB Alliance is solving this problem. We have introduced new TB cures for children in the correct dose and child-friendly forms, and are working to ensure they are available widely.
Simple Treatments, Designed for Children
Quickly dispersible in liquid. Easy for parents to give and for children of all ages to take.
Improved medicines for children with drug-sensitive TB means tablets in the correct fixed dose combinations of the three most commonly used anti-TB drugs, rifampicin + isoniazid + pyrazinamide, used for the initial two months of treatment, followed by four months of rifampicin + Isoniazid. These products offer significant advantages over previous drugs including:
- Fixed dose combinations in the correct, WHO-recommended dose – no need for crushing or chopping
- Quickly dispersible in liquid - Easy to for parents to give and for children of all ages to take
- Palatable fruit flavors
- Expected to improve treatment adherence and outcomes
-
1
The Right Medicines
The right medicines in the right doses will improve adherence and save more lives. This is an important step in improving treatment and child survival from TB, and slowing the spread of drug-resistant TB.
-
2
Simple Medicines
Simple TB medicines for children eases the TB burden on healthcare systems. Simpler TB medicines for children can allow healthcare systems to scale up treatment. Fewer pills will simplify ordering and storage.
-
3
Child-Friendly Medicines
Child-friendly medicines improve the daily lives of children and their families struggling with TB. Six months is a long time to take medicine. But the availability of treatment that tastes good and is simple to provide will ease the daily struggles of children, parents, and caregivers alike.